CLOPIDOGREL BISULFATE | N020839 | SANOFI AVENTIS US LLC
| Petition | Type | Filed | Status | Petitioner |
|---|---|---|---|---|
Public Citizen - Citizen Petition FDA-2013-P-1056 · 4 docket documents Public Citizen and Neil A. Holtzman, M.D., filed this petition under 21 U.S.C. Section 355(e)(3) requesting that the FDA add a black-box warning to clopidogrel (Plavix and generic equivalents) addressing increased risks of major and minor bleeding with use beyond 12 months following drug-eluting cor | Other | 2013-09-19 | Denied | — |
Pharmaceutical Security Institute, Inc. - Citizen Petition FDA-2011-P-0881 · 3 docket documents The Pharmaceutical Security Institute, Inc. filed this petition on November 30, 2011, requesting that the FDA take regulatory action against BetterThanMedicare.com for promoting and selling unapproved drugs, specifically foreign versions of prescription drugs including Nexium, Lipitor, and Plavix th | Other | 2011-12-09 | Denied | — |
Source: Regulations.gov. FDA citizen petitions matched by application number.
Highest NADAC/Unit
$8.20
per ea
Lowest NADAC/Unit
$8.20
per ea
Brand NDCs
1
Generic NDCs
0
| NDC Description | NADAC/Unit | Unit | Type | Generic NADAC | Effective |
|---|---|---|---|---|---|
| 00024117190PLAVIX 75 MG TABLET | $8.20 | EA | Brand | $0.0477 | 2026-06-17 |
Source: NADAC (data.medicaid.gov). Prices reflect national average acquisition costs for retail community pharmacies.
No patent or exclusivity listings for this strength.